Physician profile
Douglas E Lam
NPI 1396741211
$6,751.05
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,080 · 2020: $2,031 · 2021: $1,625 · 2022: $15.82.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,072.68 | 2019-2021 | |
| Novo Nordisk INC | $696.36 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $660.00 | 2019-2021 | |
| Amgen INC. | $460.18 | 2019-2021 | |
| Esperion Therapeutics, INC. | $452.29 | 2020-2021 | |
| Amarin Pharma, INC. | $355.86 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $327.82 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $309.73 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $308.23 | 2019-2021 | |
| Lilly USA, LLC | $303.02 | 2019-2021 | |
| Allergan, INC. | $270.85 | 2019-2020 | |
| Glaxosmithkline, LLC. | $248.67 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.06 | 2019-2021 | |
| Abbvie INC. | $199.95 | 2019-2022 | |
| Pfizer INC. | $153.27 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $113.03 | 2020-2021 | |
| Kaleo, INC. | $98.06 | 2019-2021 | |
| Aytu Biopharma, INC. | $87.42 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $83.31 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.38 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $54.84 | 2021 | |
| Tris Pharma INC | $37.75 | 2019 | |
| Daiichi Sankyo INC. | $35.43 | 2020 | |
| Cranial Technologies, INC | $34.71 | 2019-2021 | |
| Sanofi Pasteur INC. | $31.24 | 2019 | |
| Shire North American Group INC | $17.11 | 2019 | |
| Eisai INC. | $12.76 | 2019 | |
| Corcept Therapeutics | $12.43 | 2019 | |
| Sobi, INC | $12.41 | 2019 | |
| Neos Therapeutics, Lp | $12.20 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.